Alexa J Roeder on Muck Rack

Alexa J Roeder

As seen in: MDPI, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alexa J

Contact Alexa J, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies

|
By Ching-Wen Hou, Stacy Williams, Veronica Boyle, Alexa J Roeder
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Tracking Immunity: Increased number of COVID-19 boosters increases the longevity of anti-RBD and anti-RBD neutralizing antibodies.

|
By Ching-Wen Hou, Stacy Williams, Veronica Boyle, Alexa J Roeder
| medRxiv
The authors have declared no competing interest. This study was funded by Arizona State University Knowledge Enterprise, grant number NA. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Open in Who Shared View Duplicates (17) Issue with article?

Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders

|
By Douglas E. Lake, Alexa J Roeder, Maria J Gonzalez-Moa, Megan Koehler
| medRxiv
Abstract Objective: To determine if poor responders to COVID19 RNA vaccines (<50% neutralisation) after two doses would remain poor responders, or if a third dose could elicit high levels of NAbs. Design: Clinical follow up study Setting: Academic and medical institutions in USA Participants: 269 healthy individuals ranging in age from 19 to 80 (Average age: 51; 165 females and 104 males) who received either BNT162b2 (Pfizer) or mRNA1273 (Moderna) vaccines.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified